Cloopen Files Annual Report on Form 20-F for Fiscal 2025

Cloopen Group Holding (OTC: RAASY) filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on May 8, 2026.

Rhea-AI Summary

Cloopen Group Holding (OTC: RAASY) filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on May 8, 2026. The filing includes the companys audited financial statements and is available on the SEC website and the company's investor relations site.

Argus May 11 session

+4.44% close to close 1.7x rel. volume Open Argus

Details

News Market Reaction – RAASY

On May 11, the first trading day after this news, RAASY closed 4.44% above the previous close. That session’s volume was 1.7x the stock’s average daily volume.

Data tracked by StockTitan Argus for the May 11 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEIJING, May 8, 2026 /PRNewswire/ -- Cloopen Group Holding Limited (OTC: RAASY) ("Cloopen" or the "Company") today announced that it filed its annual report on Form 20-F (the "Annual Report") for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the "SEC") on May 8, 2026. The annual report on Form 20-F, which contains the Company's audited financial statements, can be accessed on the SEC's website at http://www.sec.gov as well as via the Company's investor relations website at https://ir.yuntongxun.com.

About Cloopen Group Holding Limited

Cloopen Group Holding Limited is a leading multi-capability cloud-based communications solution provider in China offering a full suite of cloud-based communications solutions, covering communications platform as a service (CPaaS), cloud-based contact centers (cloud-based CC), and cloud-based unified communications and collaborations (cloud-based UC&C). Cloopen's mission is to enhance the daily communication experience and operational productivity for enterprises. Cloopen aspires to drive the transformation of enterprise communications industry by offering innovative marketing and operational tactics and SaaS-based tools.

For more information, please visit https://ir.yuntongxun.com.

Forward-Looking Statements

This press release contains forward-looking statements made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Cloopen may also make written or oral forward-looking statements in its reports filed with or furnished to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Cloopen's beliefs and expectations as well as its financial outlook, are forward-looking statements. These forward-looking statements are based on Cloopen's current expectations and involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Cloopen's filings with the SEC. All information provided in this press release is current as of the date of the press release, and Cloopen does not undertake any obligation to update such information, except as required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement, and you are cautioned not to place undue reliance on these forward-looking statements.

For investor and media inquiries, please contact:

Cloopen Group Holding Limited
Investor Relations
Email: ir@yuntongxun.com

View original content:https://www.prnewswire.com/news-releases/cloopen-files-annual-report-on-form-20-f-for-fiscal-2025-302766981.html

SOURCE Cloopen Group Holding Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cloopen (RAASY) file with the SEC on May 8, 2026?

Cloopen filed its annual report on Form 20-F for the fiscal year ended December 31, 2025. According to Cloopen, the filing includes the company's audited financial statements and is accessible on the SEC and investor relations websites.

Where can investors access Cloopens Form 20-F filing for fiscal 2025 (RAASY)?

Investors can access the Form 20-F on the SEC website at http://www.sec.gov. According to Cloopen, the filing is also available via the company's investor relations site at https://ir.yuntongxun.com for direct download and review.

What period does Cloopens May 8, 2026 Form 20-F cover for RAASY?

The Form 20-F covers the fiscal year ended December 31, 2025. According to Cloopen, the filing contains audited financial statements for that fiscal year and related disclosure required for foreign private issuers.

Does Cloopens Form 20-F for 2025 include audited financial statements (RAASY)?

Yes, the annual report on Form 20-F includes the company's audited financial statements. According to Cloopen, those audited statements are part of the filing available on the SEC and the company's investor relations websites.

When was Cloopens 2025 Form 20-F filed with the SEC (RAASY)?

Cloopen filed the Form 20-F on May 8, 2026. According to Cloopen, the May 8 filing date reflects submission of the annual report covering the fiscal year ended December 31, 2025.

Will the Form 20-F filing affect Cloopen shareholders immediately (RAASY)?

A Form 20-F filing is a disclosure event rather than an operational action. According to Cloopen, the filing provides audited financials and disclosures; any market impact will depend on investors interpretation of those disclosed results.